MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Masimo Corporation Income Statement 2011-2026 | MASI
Annual Income Statement Masimo Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
8.96 B | 6.82 B | 9.42 B | 12 B | - | 8.96 B | 6.38 B | 4.85 B | 1.88 B | 1.41 B | - | 1.73 B | 1.21 B | 1.68 B |
Shares |
53.3 M | 52.8 M | 53.6 M | 54.7 M | - | 53.4 M | 52.3 M | 51.5 M | 51.3 M | 54.7 M | - | 56.7 M | 57.4 M | 58.8 M |
Historical Prices |
168 | 129 | 176 | 220 | 256 | 171 | 124 | 94.2 | 73.6 | 36.8 | 25.5 | 29.2 | 19.3 | 20.4 |
Net Income |
-305 M | 81.5 M | 144 M | 240 M | - | 196 M | 194 M | 125 M | 83.3 M | 72.5 M | - | 58.4 M | 62.3 M | 73.5 M |
Revenue |
2.09 B | 2.05 B | 2.04 B | 1.14 B | - | 938 M | 858 M | 790 M | 630 M | 587 M | - | 547 M | 493 M | 405 M |
Cost of Revenue |
1.09 B | 1.04 B | 977 M | 401 M | - | 309 M | 283 M | 268 M | 235 M | - | - | - | - | - |
Gross Profit |
1 B | 1 B | 1.06 B | 743 M | - | 629 M | 575 M | 522 M | 410 M | 391 M | - | 359 M | 326 M | 286 M |
Operating Income |
-267 M | 136 M | 210 M | 256 M | - | 221 M | 208 M | 184 M | 436 M | 104 M | - | 79.7 M | 85.2 M | 86.5 M |
Interest Expense |
- | - | - | 300 K | - | 328 K | 706 K | 678 K | 3.26 M | - | - | - | - | - |
EBITDA |
-164 M | 235 M | 346 M | 285 M | - | 245 M | 229 M | 204 M | 136 M | 116 M | - | 91.1 M | 94.6 M | 113 M |
Operating Expenses |
1.27 B | 867 M | 849 M | 487 M | - | 408 M | 367 M | 338 M | 290 M | 287 M | - | 279 M | 241 M | 179 M |
General and Administrative Expenses |
744 M | 664 M | 657 M | 369 M | - | 315 M | 289 M | 276 M | 253 M | 241 M | - | 216 M | 194 M | 159 M |
All numbers in USD currency
Quarterly Income Statement Masimo Corporation
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
52.2 M | 52.1 M | 54 M | 54.3 M | 54 M | 53.6 M | 53.4 M | 53.1 M | 53 M | 52.8 M | 52.8 M | 52.6 M | 52.5 M | - | 53.9 M | 55.4 M | 55.3 M | 55.1 M | 55 M | 55.2 M | - | 55 M | 54.8 M | 53.9 M | 53.7 M | 53.5 M | 53.4 M | 53.2 M | 53.1 M | 52.4 M | 52 M | 51.7 M | 51.6 M | 52.1 M | 51.7 M | 50.7 M | 51.6 M | 49.5 M | 49.3 M | 49.4 M | 52.6 M | 51 M | 51.3 M | 52.7 M | - | 54 M | 55.9 M | 56.7 M | 56.6 M | 56.5 M | 56.4 M | 57.2 M | 57.3 M | 57.2 M | 57.1 M | 58.2 M | 58.2 M | 60 M | 59.8 M | 59.6 M |
Net Income |
57.1 M | - | -100 M | 51.3 M | -171 M | - | 9.8 M | 16 M | 18.9 M | - | 15.7 M | 21.3 M | 68.3 M | - | 18.1 M | 46.6 M | 70.7 M | 57.8 M | 50.2 M | 53.4 M | - | 49.4 M | 55.8 M | 64.5 M | 52.9 M | 49.1 M | 44.9 M | 49.3 M | 46.9 M | 57.1 M | 43.9 M | 45.6 M | -7.74 M | 35.9 M | 45.1 M | 51.5 M | 215 M | 27.8 M | 30 M | 27.6 M | 21.2 B | 19.3 M | 19.4 M | 20.5 M | - | 14.9 M | 13.8 B | 22.6 B | 9.31 M | 15.6 M | 17 M | 16.4 M | 15 M | 13.8 M | 17.7 M | 15.8 M | 13.8 M | 14.8 M | 17 M | 18 M |
Revenue |
404 M | - | 372 M | 371 M | 372 M | - | 343 M | 344 M | 340 M | - | 455 M | 565 M | 328 M | - | 565 M | 304 M | 295 M | 307 M | 305 M | 299 M | - | 278 M | 301 M | 270 M | 248 M | 229 M | 230 M | 232 M | 223 M | 211 M | 212 M | 213 M | 208 M | 193 M | 192 M | 197 M | 183 M | 168 M | 173 M | 171 M | 162 M | 153 M | 156 M | 155 M | - | 144 M | 141 M | 140 M | 142 M | 131 M | 137 M | 136 M | 132 M | 119 M | 123 M | 119 M | 112 M | 104 M | 110 M | 113 M |
Cost of Revenue |
153 M | - | 141 M | 138 M | 138 M | - | 131 M | 137 M | 133 M | - | 234 M | 280 M | - | - | 307 M | 99.5 M | - | 104 M | 112 M | 102 M | - | 99.2 M | 109 M | 84 M | - | 72.7 M | 75.3 M | 80 M | - | 69.8 M | 69.5 M | 69.3 M | - | 69.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
251 M | - | 231 M | 233 M | 234 M | - | 212 M | 207 M | 207 M | - | 221 M | 285 M | 215 M | - | 258 M | 205 M | 187 M | 204 M | 193 M | 197 M | - | 179 M | 192 M | 186 M | 167 M | 156 M | 154 M | 152 M | 148 M | 141 M | 142 M | 144 M | 139 M | 124 M | 127 M | 132 M | 124 M | 110 M | 115 M | 114 M | 109 M | 102 M | 103 M | 103 M | - | 96.2 M | 93.1 M | 92.3 M | 90.5 M | 87.5 M | 91.2 M | 89.6 M | 87.2 M | 78.3 M | 81.4 M | 79.3 M | 73.6 M | 68.4 M | 75.3 M | 76.8 M |
Operating Income |
77.4 M | - | 83.6 M | 64.5 M | 78 M | - | 38.2 M | 41.9 M | 53.1 M | - | 29.3 M | 38 M | 77.4 M | - | 22.1 M | 59.7 M | 64.9 M | 67.6 M | 65.1 M | 65.7 M | - | 59.7 M | 62.2 M | 69 M | 61.6 M | 51.6 M | 52 M | 56 M | 53.9 M | 48.6 M | 51.6 M | 53.9 M | 44.7 M | 43.1 M | 43.8 M | 52.2 M | 310 M | 36.6 M | 36.4 M | 37.3 M | 32.6 M | 28.1 M | 27.8 M | 27.4 M | - | 22.3 M | 18.4 M | 30.2 M | 12.7 M | 20.7 M | 23.2 M | 23.1 M | 22.3 M | 18 M | 22.7 M | 22.3 M | 20.1 M | 18.9 M | 22.1 M | 25.4 M |
Interest Expense |
- | - | - | - | - | - | - | - | 12 M | - | 11.8 M | 11.9 M | - | - | 4.5 M | 102 K | - | 87 K | 100 K | 84 K | - | 84 K | 83 K | 84 K | - | 82 K | 80 K | 80 K | - | 7 K | 60 K | 627 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
85.5 M | - | 89.8 M | 70.9 M | 86.6 M | - | 45.8 M | 49.8 M | 63.1 M | - | 40 M | 64.1 M | 77.4 M | - | 34.1 M | 68.9 M | 64.9 M | 74.1 M | 73.9 M | 74.2 M | - | 80.9 M | 75.8 M | 75.4 M | 61.6 M | 69.2 M | 63.6 M | 61.4 M | 53.9 M | 64.6 M | 62.4 M | 59.1 M | 44.7 M | 57.4 M | 53.3 M | 56.9 M | 310 M | 49 M | 44.6 M | 41.4 M | 32.6 M | 39.7 M | 35.5 M | 31.2 M | - | 31.7 M | 24.5 M | 33.2 M | 12.7 M | 29.2 M | 28.8 M | 25.9 M | 22.3 M | 24.5 M | 26.6 M | 24.1 M | 20.1 M | 24.5 M | 26 M | 27.4 M |
Operating Expenses |
173 M | - | 147 M | 169 M | 156 M | - | 174 M | 165 M | 154 M | - | 192 M | 247 M | - | - | 236 M | 145 M | - | 136 M | 128 M | 131 M | - | 119 M | 129 M | 117 M | - | 105 M | 102 M | 95.6 M | - | 92.1 M | 90.5 M | 89.8 M | - | 81 M | 83.1 M | 80.3 M | - | 73.5 M | 78.7 M | 76.9 M | - | 74.1 M | 75.1 M | 75.7 M | - | 74 M | 74.7 M | 62.1 M | - | 66.7 M | 68.1 M | 66.4 M | - | 60.4 M | 58.8 M | 57 M | - | 49.5 M | 53.1 M | 51.4 M |
General and Administrative Expenses |
143 M | - | 116 M | 139 M | 119 M | - | 137 M | 126 M | 116 M | - | 152 M | 196 M | - | - | 188 M | 109 M | - | 101 M | 93.9 M | 96.7 M | - | 90.4 M | 98.5 M | 89.9 M | - | 80.4 M | 78.2 M | 74.2 M | - | 71.5 M | 70.4 M | 70.2 M | - | 65.7 M | 66.7 M | 66.1 M | - | 57.8 M | 63.9 M | 62.5 M | - | 59.6 M | 61.7 M | 60.8 M | - | 62.1 M | 61.3 M | 56.1 M | - | 53.1 M | 54.2 M | 52.3 M | - | 48.3 M | 47.6 M | 46.5 M | - | 40.1 M | 43.7 M | 41.5 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Masimo Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
$ 62.02 | 2.78 % | $ 12.3 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 121.69 | 7.08 % | $ 6.96 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 66.58 | 3.67 % | $ 40.4 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
$ 418.82 | 2.83 % | $ 149 B | USA |
 |
ICU Medical
ICUI
|
$ 134.93 | 3.38 % | $ 3.32 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 107.35 | 2.67 % | $ 3.44 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.14 | 5.61 % | $ 191 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 93.56 | 2.1 % | $ 2.12 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.96 | -0.51 % | $ 89.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.43 | 11.28 % | $ 35.3 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
$ 9.94 | 0.81 % | $ 84.3 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.87 | 2.1 % | $ 3.84 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 69.85 | 6.03 % | $ 3.3 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
$ 212.24 | 0.98 % | $ 20.8 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 29.86 | 5.66 % | $ 1.48 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.12 | 1.0 % | $ 188 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 132.11 | 2.76 % | $ 5.9 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 63.04 | 3.94 % | $ 3.73 B | USA |
 |
Utah Medical Products
UTMD
|
$ 67.99 | 3.75 % | $ 220 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 317.32 | 0.32 % | $ 22.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.88 | 2.49 % | $ 1.97 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 26.94 | 7.8 % | $ 1.82 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.66 | 0.41 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
$ 67.0 | 2.81 % | $ 220 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
$ 27.09 | -0.59 % | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
$ 1.88 | 2.17 % | $ 171 M | USA |
 |
Baxter International
BAX
|
$ 19.35 | 4.37 % | $ 9.93 B | USA |
 |
ResMed
RMD
|
$ 194.32 | 4.22 % | $ 28.4 B | USA |
 |
AtriCure
ATRC
|
$ 27.27 | 4.08 % | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.48 | -0.31 % | $ 288 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
$ 12.03 | 7.41 % | $ 491 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 149.56 | 2.73 % | $ 43 B | USA |
 |
Nephros
NEPH
|
$ 3.59 | -1.37 % | $ 38.1 M | USA |
 |
OraSure Technologies
OSUR
|
$ 4.17 | 5.57 % | $ 306 M | USA |
 |
Repligen Corporation
RGEN
|
$ 126.55 | 3.96 % | $ 7.12 M | USA |